explore -WSS

explore

author：explore 2025-08-11 07:58:46 - browse：3951

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Obesity drugs seen as possible treatment for liver disease MASH

focus

WSS

Robert F. Kennedy is pitching centrism on health, even on abortion

Gilead might be held responsible for not developing a drug

6 phony surgeries that take placebo to the extreme

Medical mystery: When a cough is not just a cough

Biogen Alzheimer’s drug launch off to slow start

Senators start work on Medicare physician payment reform

hotspot

explore

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

STAT readers on older presidents, polypills, Medicare, and more

Activists slam private health insurers over coverage restrictions

What should King Charles tell the public about his cancer?

Bright Health sells Medicare Advantage business to Molina

The Harvard botanist who searched for psychedelics in the Amazon

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Robert F. Kennedy is pitching centrism on health, even on abortion

Moonlake's readout produced a cash windfall. Risks remain

Private equity deals in Medicare Advantage declines

leisure time

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

A disappointing year of Humira biosimilars

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

What we’ve learned from the Aduhelm mess

Ed Silverman on new gene therapies, biosimilars, coffee, and more

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

focus

explore

leisure time